{"entity":{"id":"nct07018050","kind":"trial","name":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","aka":[],"tldr":"A phase 2 trial of QLS32015, Pomalidomide, Dexamethasone in multiple myeloma, run by Qilu Pharmaceutical Co., Ltd., now recruiting.","summary":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma is a phase 2 interventional study registered as NCT07018050 by Qilu Pharmaceutical Co., Ltd., with 160 participants planned, started 2025-09-12 and due to reach its primary completion in 2027-11. Interventions recorded: QLS32015, Pomalidomide, Dexamethasone, QL2109 or Daratumumab, Bortezomib. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07018050","url":"https://clinicaltrials.gov/study/NCT07018050"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["qls32015","pomalidomide","dexamethasone","bortezomib","lenalidomide"],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07018050","phase":"2","setting":"A Multicenter, Open-Label Phase II Study to Evaluate QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","sponsor":"Qilu Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT07018050","source":"https://clinicaltrials.gov/study/NCT07018050","fetchedAt":"2026-10-07T16:55:21.080Z","studySha256":"cbc12e6f67a6abe0f423cf6fa5283e52357799619d09d12e8148bf060f801013","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-08","leadSponsor":"Qilu Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":160,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-09-12","startedType":"actual","enrolled":160,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07018050/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"},{"id":"qls32015","kind":"drug","name":"QLS32015","route":"/drugs/qls32015/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}]}}